Views & Analysis Rare Youth Project: Can you empower the next generation of r... The next generation of rare disease advocates need a little support in getting their voices heard as part of the Rare Youth Project.
News ASH: AstraZeneca's dual-wielding CAR-T shows promise AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.